三维能量多普勒血管成像定量评估经皮局部药物灌注治疗难治性婴儿血管瘤
研究纳入47例(48处病灶)难治性婴儿血管瘤,每月行博来霉素局部灌注,治疗前及治疗后1、2个月行超声检查,计算三维体积变化及博来霉素注射量与治疗前三维体积的比值。治疗后1个月,37例(77.08%)显著改善,6处病灶(12.5%)生长受控,5处病灶(10.42%)治疗未能抑制生长;博来霉素耐受有效剂量为0.34 ± 0.03 mL/cm3,对应三维体积下降约70.27 ± 6.27%。三维能量多普勒血管成像可提供病灶内部信息并定量评估体积变化,指导介入药物的有效合理使用。
要点
- 三维能量多普勒血管成像可定量评估婴儿血管瘤体积变化,辅助指导博来霉素局部灌注剂量。
- 治疗后1个月,77.08%的病例显著改善,12.5%病灶生长受控,10.42%治疗未能抑制生长。
- 博来霉素耐受有效剂量为0.34 ± 0.03 mL/cm3,对应三维体积下降约70.27 ± 6.27%。
诊断标准与关键数值
- 治疗后1个月,37例(77.08%)显著改善,6处病灶(12.5%)生长受控,5处病灶(10.42%)治疗未能抑制生长。
- 博来霉素耐受有效剂量为0.34 ± 0.03 mL/cm3,对应三维体积下降约70.27 ± 6.27%。
临床应用与阅片要点
- 可利用三维能量多普勒血管成像定量评估病灶体积变化,辅助指导博来霉素局部灌注剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
To assess the practicality of 3-D power Doppler angiography (3-D-CPA) for local drug perfusion dosage guidance of refractory infantile hemangioma (IH) treatment, 47 cases (48 lesions) of refractory IH were selected for local bleomycin infusion (once a month). Ultrasound was performed before treatment and 1 and 2 months after the first treatment. The 3-D volume (V) change of infantile hemangiomas and the ratio of bleomycin injection to 3-D V before treatment were calculated, and statistical analysis was performed. One month after percutaneous local drug perfusion, 37 participants (77.08%) exhibited significant improvement; controlled growth was observed on six lesions (12.5%); and treatment of the remaining 5 lesions (10.42%) failed to suppress growth. The calculated tolerable and effective dose of bleomycin for refractory IH was 0.34 ± 0.03 mL/cm3; the corresponding 3-D V decreased approximately 70.27 ± 6.27%. Three-dimensional CPA can provide abundant information on internal lesions. In particular, 3-D-CPA can quantitatively assess changes in lesion volume and guide the effective and rational use of interventional drugs.
引用
- Zhang JW, Yin SY, Zhou DK, et al. Quantitative Evaluation of Percutaneous Local Drug Perfusion Against Refractory Infantile Hemangioma via 3-D Power Doppler Angiography. Ultrasound Med Biol. 2019. PMID: 31810804. doi:10.1016/j.ultrasmedbio.2019.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。